CAMBRIDGE, Mass., Nov. 22 /PRNewswire-FirstCall/ -- ViaCell, Inc. today announced that Marc D. Beer, President and Chief Executive Officer of ViaCell, will present an overview of the Company's business activities and product pipeline at the Lazard Capital Markets Life Sciences Conference on Tuesday, November 29, 2005 at 1:30 p.m. Eastern Time at the Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investor Information section of the ViaCell website at . A replay of the presentation will be available for approximately 30 days after the webcast.
ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell's reproductive health business unit commercializes ViaCord(R), a product that offers expecting families the option of preserving their baby's umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyte(TM), its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore.
ViaCell(R) and ViaCord(R) are registered trademarks and ViaCyte(TM) is a trademark of ViaCell, Inc.
For More Information Contact:
Justine E. Koenigsberg
Senior Director, Corporate Communications
(617) 914-3494
ViaCell, Inc.
CONTACT: Justine E. Koenigsberg, Senior Director, CorporateCommunications, of ViaCell, Inc., +1-617-914-3494
Web site: